Another A+H Listed Pharma Emerges; Aflibercept 8mg Approved for Once-Every-5-Months Dosing
Mabwell
Innovative Biopharmaceutical Company
GSK
Pharmaceutical R&D Manufacturer
InventisBio
Innovative Drug Developer
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
Gan&Lee Pharmaceuticals
Biological Synthetic Human Insulin Pharmaceutical R&D Manufacturer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Another A+H listed pharmaceutical company has emerged.
On April 2, according to the HKEX official website, Mabwell's IPO application passed the hearing, and it is about to achieve the layout of dual-platform listing in A+H.
Aflibercept Makes History Again.
On April 2, Regeneron announced that the FDA approved an extended dosing interval of every 5 months (every 20 weeks) for aflibercept 8mg (Eylea HD), covering indications for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Capital Information
1) Mabwell's Hong Kong IPO Application Passes Hearing
On April 2, according to the HKEX official website, Mabwell's IPO application passed the hearing, and it is about to achieve the layout of dual-platform listing in A+H.
/ 02 /
Pharmaceutical News
1) GSK's Ultra-Long-Acting IL-5 Monoclonal Antibody Approved for Second Indication in China
On April 3, according to the NMPA website, GSK's depemokimab was approved for a new indication, used for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
2) InventisBio's D-2570 Tablet Receives Clinical Approval
On April 3, according to the CDE website, InventisBio's D-2570 tablet received clinical approval for the treatment of vitiligo.
3) Hengrui Pharma's SHR-2173 Injection Receives Clinical Approval
On April 3, according to the CDE website, Hengrui Pharma's SHR-2173 injection received clinical approval for potential use in generalized myasthenia gravis.
4) Gan&Lee Pharmaceuticals Completes First Subject Dosing in Phase I Trial of GLR2037 Tablets
On April 3, Gan&Lee Pharmaceuticals announced that the Androgen Receptor-PROTAC Targeting Chimera (AR-PROTAC) GLR2037 tablet is currently undergoing Phase I clinical trials in China and has recently successfully completed the first dosing of a subject.
/ 03 /
Overseas Pharmaceutical News
1) Aflibercept 8mg Approved for Once Every 5 Months Regimen
On April 2, Regeneron announced that the FDA approved an extended dosing interval of every 5 months (every 20 weeks) for aflibercept 8mg (Eylea HD), covering indications for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
PS: Welcome to scan the QR code below to add Amino Jun's WeChat for communication.
